Healthcare M&A Strategy Shifts Toward Roll-ups
M&A strategy in the healthcare services sector is shifting, with buyout firms increasingly favoring platform roll-ups and value-based care models. To bridge valuation gaps in a volatile market, sponsors are adopting creative financing techniques such as earnouts and contingent payments. Regulatory uncertainty and reimbursement pressure remain key areas of focus during due diligence for potential acquisitions.
- The roll-up model begins with a private equity firm acquiring a large, stable "platform" practice, often with an EBITDA over $2 million, which then serves as the base for acquiring smaller "bolt-on" or "add-on" practices. A central Management Services Organization (MSO) is typically created to handle non-clinical functions like billing, HR, and marketing for all consolidated entities. - Value is created through multiple arbitrage, where smaller practices are acquired at lower EBITDA multiples than the larger, consolidated platform can command upon exit, and through operational synergies like bulk purchasing power for supplies and centralized back-office operations. - The shift to value-based care models is a significant driver of M&A because these models generate more predictable cash flows through recurring payments and shared-savings arrangements, which is attractive to buyers in a volatile reimbursement environment. Practices demonstrating strong clinical outcomes and cost controls are better positioned to attract investors. - In addition to earnouts, deal structures increasingly include equity rollovers to ensure continuity of clinical leadership post-acquisition. The performance metrics tied to earnouts are also evolving to include specific quality data and patient outcomes, not just financial targets. - Regulatory scrutiny from the Federal Trade Commission (FTC) is a major headwind, with regulators challenging deals they view as anticompetitive, specifically looking at vertical integration and its impact on market competition. This has extended deal timelines and increased due diligence costs for acquirers. - While overall healthcare M&A deal volume has declined from its peak in 2021-2022, activity has stabilized and remains above pre-pandemic levels. For instance, there were 1,373 health services deals in 2024, compared to 910 deals as of mid-December 2025. - Private equity sponsors are increasingly pivoting their investment focus away from providers with direct reimbursement risk and toward ancillary services and technology platforms, such as revenue cycle management (RCM) and AI-powered analytics tools. - High-growth subsectors like ambulatory surgery centers, behavioral health, and home-infusion services are commanding strong valuation multiples due to their perceived scalability and more favorable reimbursement outlooks.
